Expected Moves

Given the progression into late 2026, a mandated corporate update regarding strategic alternatives, potential clinical asset sales, or structural reorganization from a $0.00002 base.

Q3 2026 operational update at a $0.00001 base price to address any remaining active clinical trials or final dissolution steps for the company.

Beginning-of-year 2027 update from a $0.000005 base on clinical prospects and potential acquisition value under the deregulatory healthcare framework of President Trump.